Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Active, not recruiting · Phase 2 · NCT04450173
Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
At a glance
- Research payments reported, 2025
- $2.5M
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- University of California, Davis (with National Cancer Institute (NCI), Pharmacyclics LLC., Genentech, Inc.)
- Tested
- Ibrutinib (drug), Obinutuzumab (biological), Venetoclax (drug)
- Dates
- Started 2021-02-24; completion 2027-04
- Results posted
- Not yet
This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ibrutinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab, ibrutinib, and venetoclax together may work better in treating follicular lymphoma compared to each drug alone.
From ClinicalTrials.gov, last updated 2026-04-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $2.5M in research payments for this study in 2025 (20 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.